Edward S. Morris

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Chong Chyn Chua, Blake Hsu, Anoop Enjeti, Ashish Bajel et autres

Background For fit patients (pts), combining kinase inhibitors (midostaurin, quizartinib) with intensive chemotherapy is standard of care for FLT3mutated AML. New studies also suggest a role for kinase inhibitors (e.g. quizartinib) in modifying disease history in pts with FLT3wild-type AML (Montesinos et …

au, nz (code pays fourni par la source)

ANZTCT practice statement: sinusoidal obstruction syndrome/veno‐occlusive disease diagnosis and management

Shaun Fleming, Ashleigh Scott, John Coutsouvelis, Chris Fraser et autres

Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication which can develop after haemopoietic stem cell transplantation (HSCT) and some antibody-drug conjugates. Several SOS/VOD diagnostic and management guidelines exist, with the most recent and refined being the European Society for Blood and …

au, nz (code pays fourni par la source)

How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?

Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro et autres

Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of …

au (code pays fourni par la source)

Coagulopathy is an under-recognised complication of acquired HLH

Serena Kosciejew, Edward S. Morris, Joel Wight

Acquired haemophagocytic lymphohistiocytosis (aHLH) is a rare and often fatal process of uncontrolled cytokine release driven by the inability of natural killer cells to eliminate infected or malignant cells. Herein, we report two cases of aHLH complicated by bleeding secondary to coagulopathy …

au (code pays fourni par la source)

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Chong Chyn Chua, Natasha S. Anstee, Anoop Enjeti, Devendra Hiwase et autres

Background Adaptive resistance mechanisms leading to treatment failure in older patients (pts) receiving frontline venetoclax (VEN) combination therapies include emergence/expansion of kinase activating mutations (principally, FLT3-ITD) in pts with non-adverse (NON-ADV) karyotype AML. In both the RATIFY and QuANTUM-First trials, the FLT3 …

au (code pays fourni par la source)

An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia

Chong Chyn Chua, John Reynolds, Anoop Enjeti, Devendra Hiwase et autres

Abstract Background: Adaptive resistance mechanisms leading to treatment failure have been identified in older patients receiving venetoclax (VEN) in combination with either azacitidine or low dose cytarabine (LDAC) as frontline therapy for acute myeloid leukemia (AML). These include the expansion or secondary …

au, nz (code pays fourni par la source)

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Rose Turner, Hang Quach, Noemi Horvath, Ian Kerridge et autres

Abstract BACKGROUND Survival rates in multiple myeloma (MM) have significantly improved in recent decades with the advent of high-dose chemotherapy conditioned autologous stem cell transplantation (ASCT) and the availability of novel agents for induction therapy (Kumar SK et al. Blood 2008). Failure …

au (code pays fourni par la source)

A comprehensive study of the epidemiology of haematological malignancies in North Queensland

Karthik Nath, Rachael Boles, Theophilus I. Emeto, Oyelola A. Adegboye et autres

BACKGROUND: There is an absence of clinically relevant epidemiological data in regional Australia pertaining to haematological malignancies. AIM: To determine the incidence and geographical variation of haematological malignancies in North Queensland using a clinically appropriate disease classification. METHODS: Retrospective, observational study of …

au (code pays fourni par la source)

Upper Gastrointestinal Tract Lymphoma With Natalizumab

Lauren Gomes, Emily Watson, Matthew R. Smith, Edward S. Morris et autres

In patients with multiple sclerosis who are treated with natalizumab, new, persistent, and/or upper gastrointestinal symptoms should prompt assessment for DLBCL (Tysabri, Biogen, RTP, NC).

au (code pays fourni par la source)

Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity

Andrew Spencer, Kawa Choi, Malgorzata Gorniak, Hang Quach et autres

au (code pays fourni par la source)

A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia

Karthik Nath, Vibooshini Ganeshalingam, Barbara Ewart, Elizabeth Heyer et autres

au (code pays fourni par la source)

A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience

Elizabeth Hamilton, Karthik Nath, Venkat Vangaveti, Andrew McCutchan et autres

BACKGROUND: The Townsville Hospital is a tertiary hospital in North Queensland with one of the largest regional transplant centres in Australia, performing primarily autologous haemopoietic stem cell transplants (HSCT) for various haematological malignancies. AIMS: This single-centre, retrospective, observational study aims to describe …

au, ca (code pays fourni par la source)